Intravenous alendronate formulations
US5780455A · kind A · utility
11Cited by
4References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 24, 1994 |
| Grant date | Jul 14, 1998 |
| Priority date | — |
| Expiry date | Aug 24, 2014 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a therapy protocol for treating patients having metastatic bone disease, hypercalcemia of malignancy and/or metabolic bone disease by administering an intravenous, citrate-buffered formulation of alendronate which is isotonic with human blood.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.